Cargando…

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis

BACKGROUND: OX40 (CD134) is expressed in lesional but not healthy skin of patients with psoriasis. KHK4083 is a fully human monoclonal antibody against OX40. OBJECTIVE: The primary aim of this first‐in‐human phase 1 study was to determine the safety and tolerability of ascending single doses of KHK4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papp, K.A., Gooderham, M.J., Girard, G., Raman, M., Strout, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles and Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575535/ https://www.ncbi.nlm.nih.gov/pubmed/28556418 http://dx.doi.org/10.1111/jdv.14313

Ejemplares similares

Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis
por: Kierkus, Jaroslaw, et al.
Publicado: (2020)

Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis
por: Kierkus, Jaroslaw, et al.
Publicado: (2020)

A Phase 1 Study of KHK4083: A Single‐Blind, Randomized, Placebo‐Controlled Single‐Ascending‐Dose Study in Healthy Adults and an Open‐Label Multiple‐Dose Study in Patients With Ulcerative Colitis
por: Furihata, Kenichi, et al.
Publicado: (2021)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
por: Kowalzick, Lutz
Publicado: (2009)

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
por: Gooderham, Melinda, et al.
Publicado: (2022)

Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy
por: Imafuku, Shinichi, et al.
Publicado: (2018)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis
por: Langewouters, A. M. G., et al.
Publicado: (2007)

Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America
por: Papp, Kim A., et al.
Publicado: (2019)

Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
por: Papp, Kim A., et al.
Publicado: (2022)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae
por: Hübner, Marc P., et al.
Publicado: (2019)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
por: Kimball, A.B., et al.
Publicado: (2019)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody
por: Papp, K.A., et al.
Publicado: (2018)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Subarachnoid Hemorrhage in Type 1 Diabetes: A prospective cohort study of 4,083 patients with diabetes
por: Korja, Miikka, et al.
Publicado: (2013)

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis
por: Anil Kumar, Mysore S., et al.
Publicado: (2018)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

Correction of gene model annotations improves isoform abundance estimates: the example of ketohexokinase ( Khk)
por: Chabbert, Christophe D., et al.
Publicado: (2019)

KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid
por: Velázquez, Ana Magdalena, et al.
Publicado: (2022)

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
por: Li, Qian, et al.
Publicado: (2022)

Characterizing Outcomes and Unmet Needs Among Patients in the United States with Mild-to-Moderate Plaque Psoriasis Using Prescription Topicals
por: Gupta, Shaloo, et al.
Publicado: (2021)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r5r1ssn2ofvt31ffi4enqb11k9